evipedia.ai
← Back

Curcumin for Health & Longevity

Created on 10/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Curcumin, the yellow compound in turmeric, is a supplement taken mainly for joint pain, blood sugar and healthy aging. Its most consistent benefits are modest: less arthritis pain and stiffness, lower blood sugar in prediabetes or diabetes, slight weight loss, and relief of depressive and anxiety symptoms. Rare but sometimes severe liver injury, especially with high-absorption products, is the main safety concern; its value for slowing aging remains unproven. (Full Review)

Protocol

Standard extract (joints)
About 1,000 mg/day curcumin
Trials generally used 500–2,000 mg/day curcuminoids; osteoarthritis protocols run at least 12 weeks
Time of day
With a fat-containing meal
Aids absorption; most positive trials split doses twice daily, matching the roughly 7-hour half-life
Metabolic regimen
1,500 mg/day curcuminoids
As 250 mg capsules, three twice daily, for 9 months in prediabetes
Time to effect
Joint pain
8–12 weeks
Osteoarthritis pain relief
Blood sugar
3–9 months
Glycemic changes
Mood
4–8 weeks
Depressive symptoms in major depressive disorder

Benefits

Contraindications
  • Gallbladder or bile duct disorders (including gallstones and bile duct obstruction)
  • Under 18 years of age
  • Prior turmeric- or curcumin-associated liver injury
  • Existing liver disease unless supervised (including ALT at or above 3 times the upper limit of normal)
  • Tamoxifen use
  • Pregnancy or breastfeeding (concentrated supplements)
  • Iron-deficiency anemia
  • Recurrent calcium oxalate kidney stones
    •
Key Interactions
  • BCRP substrates (sulfasalazine, rosuvastatin, methotrexate): raised drug exposure (theoretical for rosuvastatin and methotrexate); monitoring drug effects
  • P-glycoprotein substrates (talinolol, digoxin): beta-blocker effect may shift either way (digoxin theoretical); heart rate monitoring
  • Anticoagulants and antiplatelets (warfarin, clopidogrel): INR rise in a case report; INR checks
  • Glucose-lowering drugs (sulfonylureas, insulin): additive glucose lowering (theoretical); glucose monitoring when starting
  • Immunosuppressants (tacrolimus, cyclosporine): altered levels (theoretical); drug-level monitoring with the transplant team
  • Irinotecan: antioxidant interference with other chemotherapy (theoretical); only with the oncologist's agreement
  • NSAIDs (ibuprofen, naproxen): additive stomach irritation or bleeding at high doses (theoretical)
  • Paracetamol (acetaminophen): combined liver burden (theoretical)
  • Iron supplements: reduced iron absorption (theoretical); separating doses by 2–4 hours
  • Piperine (black pepper extract): raises curcumin exposure; may raise other drug levels (theoretical)
  • Supplements with antiplatelet effects (fish oil, ginkgo): additive bleeding tendency (theoretical); pausing before surgery
  • Supplements with glucose-lowering effects (berberine, cinnamon extract): additive glucose lowering (theoretical); glucose monitoring
  • Botanicals with liver-injury reports (green tea extract, ashwagandha): additive liver risk (theoretical); not combining several such products, plus liver enzyme checks
  • Surgery and procedures: additive bleeding (theoretical); stopping 1–2 weeks beforehand is common practice
  • Alcohol: additional liver burden (theoretical); limited intake and liver enzyme monitoring
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Liver injury; gastrointestinal adverse effects; iron-deficiency anemia; kidney stone risk from oxalate; lead contamination of turmeric products; severe skin reaction
    •
  • Speculative: Biliary pain in gallstone disease; bleeding tendency
    •

Monitoring

Marker Target Why
ALT and AST ALT about 7–55 U/L; AST about 8–48 U/L Safety check: rise stops use
Total bilirubin 0.1–1.2 mg/dL Safety check: rise stops use
Ferritin and hemoglobin Ferritin 24–336 ng/mL in men, 11–307 ng/mL in women; hemoglobin 13.5–17.5 g/dL in men, 12.0–15.5 g/dL in women Safety check: fall changes use
Fasting glucose and HbA1c Fasting glucose below 100 mg/dL; HbA1c below 5.7% Expected to change
hs-CRP Below 1.0 mg/L Expected to change
INR (warfarin users only) No established target; individual's prescribed therapeutic range Safety check: change alters use
24-hour urine oxalate (stone formers only) Below 40 mg/day Safety check: rise stops use

Cadence: Baseline before starting; liver tests at 4–12 weeks after starting, then every 6–12 months; glucose markers and CRP at 3 months, then every 6–12 months; ferritin annually; INR within 1–2 weeks of starting or changing dose for warfarin users

Qualitative Assessment

  • Joint pain and stiffness: 0–10 pain rating at baseline and 12 weeks
  • Mood and energy: brief depression or fatigue questionnaire every 4–8 weeks
  • Digestive tolerance: nausea, diarrhea or reflux after doses
  • Liver warning signs: yellowing of the eyes or skin, dark urine, nausea or upper abdominal pain
  • Exercise recovery: perceived soreness 24–72 hours after hard sessions
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.